552 related articles for article (PubMed ID: 31785413)
1. The evolving role of PD-L1 testing in patients with metastatic urothelial carcinoma.
Powles T; Walker J; Andrew Williams J; Bellmunt J
Cancer Treat Rev; 2020 Jan; 82():101925. PubMed ID: 31785413
[TBL] [Abstract][Full Text] [Related]
2. First-line checkpoint inhibitors in PD-L1-positive patients with advanced urothelial carcinoma.
Tsimafeyeu I; Tjulandin S
BJU Int; 2019 Apr; 123(4):563-565. PubMed ID: 30457694
[No Abstract] [Full Text] [Related]
3. [First-line treatment of metastatic urothelial carcinoma : Update immuno-oncology].
Zacharis A; Grüllich C
Urologe A; 2020 Jul; 59(7):797-803. PubMed ID: 32500171
[TBL] [Abstract][Full Text] [Related]
4. Pembrolizumab in the treatment of advanced urothelial cancer.
Lundgren KT; Farina MS; Bellmunt J
Future Oncol; 2017 Dec; 13(30):2745-2758. PubMed ID: 29219016
[TBL] [Abstract][Full Text] [Related]
5. FDA Approval Summary: Atezolizumab or Pembrolizumab for the Treatment of Patients with Advanced Urothelial Carcinoma Ineligible for Cisplatin-Containing Chemotherapy.
Suzman DL; Agrawal S; Ning YM; Maher VE; Fernandes LL; Karuri S; Tang S; Sridhara R; Schroeder J; Goldberg KB; Ibrahim A; McKee AE; Pazdur R; Beaver JA
Oncologist; 2019 Apr; 24(4):563-569. PubMed ID: 30541754
[TBL] [Abstract][Full Text] [Related]
6. PD-L1 Expression in Urothelial Carcinoma With Predominant or Pure Variant Histology: Concordance Among 3 Commonly Used and Commercially Available Antibodies.
Reis H; Serrette R; Posada J; Lu V; Chen YB; Gopalan A; Fine SW; Tickoo SK; Sirintrapun SJ; Iyer G; Funt SA; Teo MY; Rosenberg JE; Bajorin DF; Dalbagni G; Bochner BH; Solit DB; Reuter VE; Al-Ahmadie HA
Am J Surg Pathol; 2019 Jul; 43(7):920-927. PubMed ID: 31135485
[TBL] [Abstract][Full Text] [Related]
7. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial.
Rosenberg JE; Hoffman-Censits J; Powles T; van der Heijden MS; Balar AV; Necchi A; Dawson N; O'Donnell PH; Balmanoukian A; Loriot Y; Srinivas S; Retz MM; Grivas P; Joseph RW; Galsky MD; Fleming MT; Petrylak DP; Perez-Gracia JL; Burris HA; Castellano D; Canil C; Bellmunt J; Bajorin D; Nickles D; Bourgon R; Frampton GM; Cui N; Mariathasan S; Abidoye O; Fine GD; Dreicer R
Lancet; 2016 May; 387(10031):1909-20. PubMed ID: 26952546
[TBL] [Abstract][Full Text] [Related]
8. Immunotherapy for metastatic urothelial carcinoma: status quo and the future.
Necchi A; Rink M; Giannatempo P; Raggi D; Xylinas E
Curr Opin Urol; 2018 Jan; 28(1):1-7. PubMed ID: 29028766
[TBL] [Abstract][Full Text] [Related]
9. Performance of the Food and Drug Administration/EMA-approved programmed cell death ligand-1 assays in urothelial carcinoma with emphasis on therapy stratification for first-line use of atezolizumab and pembrolizumab.
Eckstein M; Erben P; Kriegmair MC; Worst TS; Weiß CA; Wirtz RM; Wach S; Stoehr R; Sikic D; Geppert CI; Weyerer V; Bertz S; Breyer J; Otto W; Keck B; Burger M; Taubert H; Weichert W; Wullich B; Bolenz C; Hartmann A; Erlmeier F
Eur J Cancer; 2019 Jan; 106():234-243. PubMed ID: 30528808
[TBL] [Abstract][Full Text] [Related]
10. Anti-Programmed Cell Death 1/Ligand 1 (PD-1/PD-L1) Antibodies for the Treatment of Urothelial Carcinoma: State of the Art and Future Development.
Powles T; Necchi A; Rosen G; Hariharan S; Apolo AB
Clin Genitourin Cancer; 2018 Apr; 16(2):117-129. PubMed ID: 29325739
[TBL] [Abstract][Full Text] [Related]
11. From Clinical Trials to Real-life Clinical Practice: The Role of Immunotherapy with PD-1/PD-L1 Inhibitors in Advanced Urothelial Carcinoma.
Hussain SA; Birtle A; Crabb S; Huddart R; Small D; Summerhayes M; Jones R; Protheroe A
Eur Urol Oncol; 2018 Dec; 1(6):486-500. PubMed ID: 31158093
[TBL] [Abstract][Full Text] [Related]
12. Multicentric analytical comparability study of programmed death-ligand 1 expression on tumor-infiltrating immune cells and tumor cells in urothelial bladder cancer using four clinically developed immunohistochemistry assays.
Schwamborn K; Ammann JU; Knüchel R; Hartmann A; Baretton G; Lasitschka F; Schirmacher P; Braunschweig T; Tauber R; Erlmeier F; Hieke-Schulz S; Weichert W
Virchows Arch; 2019 Nov; 475(5):599-608. PubMed ID: 31267201
[TBL] [Abstract][Full Text] [Related]
13. Immunotherapy for Urothelial Carcinoma: Current Evidence and Future Directions.
Tripathi A; Plimack ER
Curr Urol Rep; 2018 Nov; 19(12):109. PubMed ID: 30406502
[TBL] [Abstract][Full Text] [Related]
14. Anti-PD-L1/TGFβR2 (M7824) fusion protein induces immunogenic modulation of human urothelial carcinoma cell lines, rendering them more susceptible to immune-mediated recognition and lysis.
Grenga I; Donahue RN; Gargulak ML; Lepone LM; Roselli M; Bilusic M; Schlom J
Urol Oncol; 2018 Mar; 36(3):93.e1-93.e11. PubMed ID: 29103968
[TBL] [Abstract][Full Text] [Related]
15. The European Medicines Agency review of the initial application of atezolizumab and the role of PD-L1 expression as biomarker for checkpoint inhibitors.
Araujo-Fernandez I; Delgado J; Moscetti L; Sarac SB; Zander H; Mueller-Egert S; Dunder K; Pean E; Bergmann L; Enzmann H; Pignatti F
ESMO Open; 2021 Feb; 6(1):100008. PubMed ID: 33399074
[TBL] [Abstract][Full Text] [Related]
16. Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial.
Balar AV; Galsky MD; Rosenberg JE; Powles T; Petrylak DP; Bellmunt J; Loriot Y; Necchi A; Hoffman-Censits J; Perez-Gracia JL; Dawson NA; van der Heijden MS; Dreicer R; Srinivas S; Retz MM; Joseph RW; Drakaki A; Vaishampayan UN; Sridhar SS; Quinn DI; Durán I; Shaffer DR; Eigl BJ; Grivas PD; Yu EY; Li S; Kadel EE; Boyd Z; Bourgon R; Hegde PS; Mariathasan S; Thåström A; Abidoye OO; Fine GD; Bajorin DF;
Lancet; 2017 Jan; 389(10064):67-76. PubMed ID: 27939400
[TBL] [Abstract][Full Text] [Related]
17. Outcomes in patients with advanced urothelial carcinoma after discontinuation of programmed death (PD)-1 or PD ligand 1 inhibitor therapy.
Sonpavde G; Pond GR; Mullane S; Ramirez AA; Vogelzang NJ; Necchi A; Powles T; Bellmunt J
BJU Int; 2017 Apr; 119(4):579-584. PubMed ID: 27700015
[TBL] [Abstract][Full Text] [Related]
18. A review of the PD-1/PD-L1 checkpoint in bladder cancer: From mediator of immune escape to target for treatment.
Zhou TC; Sankin AI; Porcelli SA; Perlin DS; Schoenberg MP; Zang X
Urol Oncol; 2017 Jan; 35(1):14-20. PubMed ID: 27816403
[TBL] [Abstract][Full Text] [Related]
19. PD-L1 expression in advanced NSCLC: Insights into risk stratification and treatment selection from a systematic literature review.
Brody R; Zhang Y; Ballas M; Siddiqui MK; Gupta P; Barker C; Midha A; Walker J
Lung Cancer; 2017 Oct; 112():200-215. PubMed ID: 29191596
[TBL] [Abstract][Full Text] [Related]
20. A drug safety evaluation of atezolizumab in locally advanced or metastatic urothelial carcinoma.
Economopoulou P; Kotsantis I; Bamias A
Expert Opin Drug Saf; 2020 Aug; 19(8):955-960. PubMed ID: 32657630
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
